Y-mAbs/$YMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Y-mAbs
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Ticker
$YMAB
Sector
Health
Primary listing
Employees
104
Headquarters
Website
Y-mAbs Metrics
BasicAdvanced
$387M
-
-$0.63
0.52
-
Price and volume
Market cap
$387M
Beta
0.52
52-week high
$15.70
52-week low
$3.55
Average daily volume
958K
Financial strength
Current ratio
4.771
Quick ratio
4.117
Long term debt to equity
0.165
Total debt to equity
0.674
Profitability
EBITDA (TTM)
-23.374
Gross margin (TTM)
81.83%
Net profit margin (TTM)
-31.84%
Operating margin (TTM)
-26.87%
Effective tax rate (TTM)
1.05%
Revenue per employee (TTM)
$850,000
Management effectiveness
Return on assets (TTM)
-12.62%
Return on equity (TTM)
-29.93%
Valuation
Price to revenue (TTM)
4.292
Price to book
4.31
Price to tangible book (TTM)
4.42
Price to free cash flow (TTM)
-19.741
Free cash flow yield (TTM)
-5.07%
Free cash flow per share (TTM)
-0.432
Growth
Revenue change (TTM)
4.92%
Earnings per share change (TTM)
27.58%
3-year revenue growth (CAGR)
30.38%
3-year earnings per share growth (CAGR)
-38.15%
What the Analysts think about Y-mAbs
Analyst ratings (Buy, Hold, Sell) for Y-mAbs stock.
Bulls say / Bears say
DANYELZA net product revenues rose 8% year-over-year to $20.9 million in Q1 2025, demonstrating solid commercial traction. (GlobeNewswire)
Naxitamab-gqgk (DANYELZA) was recommended by NCCN as a Category 2A treatment option for high-risk neuroblastoma, reinforcing its clinical adoption potential. (GlobeNewswire)
The company presented complete Part A data from its GD2-SADA Phase 1 trial at the ANR meeting, showing tolerability with no dose-limiting toxicities, validating its radiopharmaceutical pipeline. (Y-mAbs IR)
U.S. DANYELZA net product revenues declined 28% year-over-year to $13.4 million in Q1 2025, indicating U.S. market penetration challenges. (GlobeNewswire)
Gross margin decreased from 89% to 86% in Q1 2025 due to a higher mix of lower-margin ex-U.S. sales, compressing overall profitability. (GlobeNewswire)
Cash and cash equivalents fell to $60.3 million as of March 31, 2025, while full-year cash investment is expected at $25 million–$30 million, suggesting potential need for additional financing before the projected 2027 runway. (GlobeNewswire)(GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 25 Jul 2025.
Y-mAbs Financial Performance
Revenues and expenses
Y-mAbs Earnings Performance
Company profitability
Y-mAbs News
AllArticlesVideos
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders
Business Wire·15 hours ago
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
Business Wire·1 day ago
YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is Fair to Shareholders
Business Wire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Y-mAbs stock?
Y-mAbs (YMAB) has a market cap of $387M as of August 09, 2025.
What is the P/E ratio for Y-mAbs stock?
The price to earnings (P/E) ratio for Y-mAbs (YMAB) stock is 0 as of August 09, 2025.
Does Y-mAbs stock pay dividends?
No, Y-mAbs (YMAB) stock does not pay dividends to its shareholders as of August 09, 2025.
When is the next Y-mAbs dividend payment date?
Y-mAbs (YMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Y-mAbs?
Y-mAbs (YMAB) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.